Hyperkalaemia (HK) occurrence and recurrence are frequent in advanced CKD*, creating a perfect storm for cardiovascular events and death, says Professor Juan-Jesus Carrero from the Karolinska Institute, Solna, Sweden, at ERA-EDTA 2020. Given these risks, acutely elevated potassium (K+) should merit clinical attention.
In this third issue we take
a look at how empagliflozin made a bold impact on clinical guidelines across
multiple specialties. We will explore how existing treatment recommendations
were altered, and summarise the current guidelines and future perspectives of
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
mechanisms for its cardiovascular benefits.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Hypertension (HPT) is defined as a persistent elevation of systolic blood pressure (BP) of 140 mmHg or greater and/or diastolic BP of 90 mmHg or greater, taken at least twice ontwo separate occasions. The most recent National Health and Morbidity Survey (NHMS) 2015 that focuses on noncommunicable diseases showed that among adults aged 18 years and older, there was an increase in the prevalence of HPT from 33.6% in 2011 to 35.3%. While the proportion of patients with HPT who have attained good BP control has increased from 34.7% in 2011 to 37.4%, the awareness of the condition among patients remains poor. The prevalence of undiagnosed HPT remains high; hence, it is recommended that every adult aged 18 years and older to check their BP at least once annually, and more frequently in those with risk factors (eg, family history, obese).
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Small dense low-density lipoprotein cholesterol (sd-LDL-C) is a strong predictor of stroke severity and intracranial artery calcification (IAC) in patients with acute ischaemic stroke (AIS), a study has shown.